Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for BDC-4182 in Cancer, Gastric cancer. The expected timing is based on the latest available company guidance and may change.
5/12/25- Initiated participant enrollment. 8/14/25- Trial ongoing, to expand in multiple countries in H2 2025. 10/1/25- Initial data adjusted to Q3 2026. 11/12/25:- Trial actively enrolling gastric and gastroesophageal cancer patients. Protocol amended for step-up dosing after strong immune responses at initial dose levels. Initial Ph1 data still expected in Q3 2026. 03/12/26:- Ph1 gastric and gastroesophageal cancer trial ongoing; initial data still expected in Q3 2026. 05/12/26:- Ph1/2 gastric cancer trial ongoing; initial data reaffirmed for Q3 2026; cash runway funds dose escalation completion. 08/11/26:- Cohort 4 ongoing. Well tolerated with activity. Initial Ph1/2 data expected in Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.